New antibody drug HB0043 gets first human safety check
NCT ID NCT06999083
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the safety and tolerability of a single dose of HB0043, a lab-made antibody that targets two inflammatory proteins (IL-17A and IL-36R), in 52 healthy adults aged 18 to 55. Participants received either the drug or a placebo, and researchers monitored for side effects and how the drug moved through the body. Since this is an early Phase 1 trial, it does not test whether the drug treats any disease—only that it is safe enough to study further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HB0043 (a bispecific antibody targeting IL-17A and IL-36R)
What this could lead to
If successful, this could pave the way for future studies of HB0043 in inflammatory diseases like psoriasis or arthritis.
What could go wrong
This is an early Phase 1 trial in healthy volunteers, so it only tests safety and dosing—not whether the drug works for any disease. Side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New Zealand Clinical Research , Grafton, Auckland, 3 Ferncroft Street,
Auckland, Grafton, New Zealand